High throughput microscopy quantifies regulation of estrogen receptor

High throughput microscopy that uses robots and special microscopes and techniques to generate thousands of images of a cell in a short time enabled researchers at Baylor College of Medicine in Houston to describe how the genetic message of estrogen receptor-alpha is regulated, a finding that could have implications for breast cancer.

In a report in the current issue of the Public Library of Science-ONE, Dr. Michael A. Mancini and his colleagues showed that estrogen receptor-alpha’s response depends on the manner of regulation.

“All of this is leading to personalized medicine, said Mancini, associate professor of molecular and cellular biology at BCM and director of the Integrated Microscopy Core at the College. “We will some day be able to get functional assays of this kind on individual people. We have laid the groundwork to do patient samples.”

Estrogen receptor activity is regulated in two manners. One is called ligand- or steroid-dependent in which the receptor has to bind to a small molecule to become active. The other is independent of the ligand and requires the action of another kind of molecule, such as a growth factor to become active.

Mancini, also a researcher in the Dan L. Duncan Cancer Center at BCM, and Dr. Valeria Berno, a postdoctoral associate in his lab, along with colleagues established a system that allows multiple quantitative “single-cell” analyses of how estrogen receptor regulates that transcription of genetic messages. (Transcription refers to the translation of a genetic message into the protein that carries out a function within a cell. Various factors can influence the extent to which such messages are translated within the cell).

The cell line contained elements that lit up when estrogen receptor is activated. The estrogen receptor was marked with a green fluorescent protein. When it lights up, it enables researchers to “see” through a microscope the actions of a protein on the estrogen receptor.

The technique allowed them to see the receptor move in and out of the nucleus, bind to DNA and remodel the chromatin molecule that makes up the cell’s chromosomes.

The system enabled them to differentiate the manner in which estrogen receptor responded to a ligand (estradiol) and to a growth factor (epidermal growth factor).

“This would never have been possible without the combination of manual and high throughput microscopy,” said Mancini. The high throughput approach involves using a robot to fix slides with cells, stain them, put them under a microscope, focus and take photographs.

“You put it in the microscope, come back and all the pictures are taken,” said Mancini. This particular experiment involved tens of thousands of such photographs, he said.

“You can look at DNA occupancy of receptor and coregulators, chromatin modeling and transcription (the translation of the genetic message) at the same time in the same image, this is a good example of why the approach is being called “high content analysis” he said. “What is really exciting is not only how fast we can collect the data, but the image analysis toolbox is expanding at a remarkably fast rate. This is the beginning of high throughput systems biology.”

Maureen Mancini, a research associate at BCM, helped overcome a major hurdle by making the cell line that allowed the scientists to see what was happening.

“We are able to look at the receptor affected by the two different types of stimulation. They are now distinguishable because of this research,” he said.

Source: Baylor College of Medicine

Related stories:

Protein-based tumor biomarker predicts breast-cancer survival
The first and largest clinical trial of its kind confirms that a protein called p27 may be a valuable tool for predicting survival after a diagnosis of breast cancer.
Researchers improve design of genetic on-off switches
Researchers at the University of Illinois at Urbana-Champaign have set a new standard in the design and engineering of nuclear hormone receptor-based genetic on-off switches, without causing new problems or aggravating existing ones.
1 step back ... 2 steps forward
Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposium may change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.
Growth factor predicts poor outcome in breast cancer
The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.
Scientists uncover molecule that keeps pathogens like salmonella in check
Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick.
Risk assessment plays key role in long-term treatment of breast cancer
Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.
Improved estrogen reception may sharpen fuzzy memory
Estrogen treatments may sharpen mental performance in women with certain medical conditions, but University of Florida researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs.
Team discovers new inhibitors of estrogen-dependent breast cancer cells
Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described today at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.

News discussion:

Medicine & Health news